Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data-Reference-Cited by-同舟云学术

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

Published:2014-10 Issue:11 Volume:15 Page:1254-1262
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rossi Antonio,Chiodini Paolo,Sun Jong-Mu,O'Brien Mary E R,von Plessen Christian,Barata Fernando,Park Keunchil,Popat Sanjay,Bergman Bengt,Parente Barbara,Gallo Ciro,Gridelli Cesare,Perrone Francesco,Di Maio Massimo

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guidelines update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2011

3. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Peters;Ann Oncol,2012

4. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease;Besse;Ann Oncol,2014

5. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study;Ciuleanu;Lancet,2009

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress;Cell Death Discovery;2024-01-18

2. First-line therapy;Lung Cancer;2024

3. Survival after radiofrequency ablation and/or chemotherapy for lung cancer and pulmonary metastases: a systematic review and meta-analysis;Frontiers in Immunology;2023-10-06

4. The effect of radiotherapy and surgery on stage IIIA/B NSCLC patients treated with chemotherapy;INT J RADIAT RES;2023

5. Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia;PharmacoEconomics;2023-06-25